A Skolkovo resident Infectex, a portfolio company of Maxwell Biotech Venture Fund, established with the participation of RVC develops an innovative drug SQ109 for the multidrug-resistant tuberculosis (MDR-TB) treatment together with an American biotech company Sequella.
Prof. Sergey Borisov, chief study coordinator, deputy director for science and clinical work at Moscow Research Center for TB control of the Moscow Department of Health tells TV “Center” about the drug development progress.
PR manager at Maxwell Biotech Group;
Tel.: +7 (495) 411-6992